8-K: Cencora Reaffirms FY26 EPS Guidance Amid Walgreens Business Shift

Cencora, Inc. has reaffirmed its fiscal year 2026 adjusted diluted EPS guidance of $17.75 to $17.95, indicating that a planned shift of certain Walgreens volume outside the company was fully anticipated and accounted for.

Summary

• Cencora, Inc. is filing a Form 8-K to disclose that certain Walgreens volume, separate from their prime vendor agreement, began moving outside the company starting July 1, 2026.
• The prime vendor agreement, which represents the majority of Cencora's business with Walgreens, remains unchanged.
• This business shift was anticipated and factored into Cencora's previously issued commentary on fourth-quarter expectations for its U.S. Healthcare Solutions segment.
• The company is reaffirming its previously issued adjusted diluted Earnings Per Share (EPS) guidance range of $17.75 to $17.95 for the fiscal year 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reaffirms guidance despite a contemplated shift in business with a major client.

Positives

• Reaffirmation of previously issued adjusted diluted EPS guidance for fiscal year 2026 ($17.75 to $17.95), indicating financial stability and predictability.
• The prime vendor agreement with Walgreens, which constitutes the vast majority of their business, remains unaffected by the volume shift.
• The company explicitly states that the business shift was fully contemplated and accounted for in prior financial commentary, suggesting proactive management and accurate forecasting.

Negatives

• A portion of Walgreens' volume is moving outside of Cencora's servicing, starting July 1, 2026.
• While the prime vendor agreement is unaffected, the loss of any volume, even if anticipated, represents a reduction in business scope.

Risks

• Potential for further shifts in business volume from key clients like Walgreens, impacting future revenue streams.
• Uncertainty regarding the long-term relationship with Walgreens beyond the prime vendor agreement.
• The risk that actual results could vary materially from forward-looking statements due to unforeseen circumstances, as detailed in the company's SEC filings.

Future Outlook

Cencora is reaffirming its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026, indicating confidence in meeting these targets despite the contemplated shift in Walgreens volume.

Management Comments

• The prime vendor agreement, which remains unchanged, constitutes the vast majority of the Company's business with Walgreens.
• This was fully contemplated in Cencoras August 5, 2026 commentary on fourth quarter expectations for its U.S. Healthcare Solutions segment.
• Cencora is reaffirming its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026.

Industry Context

StockSavvy.ai notes that shifts in volume from major clients are not uncommon in the pharmaceutical distribution and healthcare solutions sector. The key factor here is Cencora's proactive communication and reaffirmation of guidance, suggesting they have managed this transition effectively within their existing financial projections.

Stakeholder Impact

• Shareholders: The reaffirmation of EPS guidance provides a degree of certainty regarding near-term financial performance.
• Employees: Potential impact on roles within the U.S. Healthcare Solutions segment related to the shifted Walgreens volume, though the prime vendor agreement's stability mitigates broader concerns.
• Suppliers/Creditors: The stability of the prime vendor agreement suggests continued strong business operations, which should reassure suppliers and creditors.

Next Steps

• Continue to service the prime vendor agreement with Walgreens, which remains unchanged.
• Monitor the impact of the volume shift on the U.S. Healthcare Solutions segment.
• Achieve the reaffirmed adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026.

Key Dates

Recommendation

The filing is a routine disclosure reaffirming guidance despite a known business shift. While the shift itself is a negative, the company's proactive management and reaffirmation of guidance suggest it's already priced in and managed. This warrants a 'hold' as there's no new information to significantly alter the investment thesis.

Keywords

Cencora, Walgreens, EPS Guidance, U.S. Healthcare Solutions, Prime Vendor Agreement, Volume Shift, Form 8-K, Fiscal Year 2026